Research programme: skin disorders therapeutics - Valeant Pharmaceuticals International

Drug Profile

Research programme: skin disorders therapeutics - Valeant Pharmaceuticals International

Latest Information Update: 10 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicis Pharmaceutical Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Skin disorders

Most Recent Events

  • 06 Apr 2005 aaiPharma is experiencing financial difficulty
  • 20 Dec 2004 Medicis has been granted an exclusive, worldwide right to Ansata Therapeutics early-stage, proprietary antimicrobial peptide technology
  • 01 Jul 2002 Preclinical trials in Skin disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top